...coronary syndrome. Fulcrum is also evaluating preclinical compounds against three additional targets for muscle diseases: UTRN...
...Dystrophia myotonica-protein kinase; DUX4 - double homeobox 4; FXN (FRDA) - Frataxin; UTRN - Utrophin Chris...

...well as a secondary endpoint measuring muscle damage via biopsy. Ezutromid is a small molecule utrophin (UTRN)...
...has exclusive rights in Europe, Turkey and the Commonwealth of Independent States (CIS) to Summit's UTRN...
...NASDAQ:SMMT), Abingdon, U.K. Product: Ezutromid (SMT C1100) Business: Musculoskeletal Molecular target: Utrophin (UTRN) Description: Small molecule UTRN...

...as a secondary endpoint measuring muscle damage via biopsy. Ezutromid is a small molecule utrophin UTRN...
...CIS) to Summit's UTRN modulator pipeline for DMD (see "Sarepta Gets Territorial Rights to Summit's Utrophin...
...to $129.27 Wednesday. Jennie Walters ezutromid (SMT C1100, bmn 195, VOX C1100, VOXC 1100) Sarepta Therapeutics Inc. Summit Therapeutics plc Utrophin (UTRN)...

...in MRI leg muscle parameters and pharmacokinetics. Secondary endpoints include muscle regeneration biomarkers, change in UTRN...
...biopsies and safety. Top-line 48-week data are expected in 3Q18. Ezutromid is a small molecule utrophin (UTRN)...
...Product: Ezutromid (SMT C1100) (formerly BMN 195) Business: Musculoskeletal Molecular target: Utrophin (UTRN) Description: Small molecule UTRN...

...long-term, extension phase. Top-line 48-week data are expected in 3Q18. Ezutromid is a small molecule utrophin (UTRN)...
...has exclusive rights in Europe, Turkey and the Commonwealth of Independent States (CIS) to Summit’s UTRN...
...in the EU. On Thursday, Sarepta gained $1.83 to $67.61. Chris Lieu ezutromid SMT C1100 Sarepta Therapeutics Inc. Summit Therapeutics plc Utrophin (UTRN)...

...reduced disease symptoms by activating liver expression of IL-10 or klotho, PDX1, and klotho or UTRN...
...the two-vector system reduced DMD symptoms after birth by activating the muscle regulators FST or UTRN...
...and duodenal homeobox 1 RELA (p65) - v-rel reticuloendotheliosis viral oncogene homolog A UTRN - Utrophin...

...a small molecule modulator of utrophin, ezutromid from Summit Therapeutics plc will face similar challenges. Utrophin...
...replaced by dystrophin as the muscle matures. He said a utrophin modulator seeks to maintain utrophin...
...muscle fibers and not on mature fibers, to identify utrophin-expressing muscle. But Roblin noted measuring utrophin...

...leg muscle parameters and pharmacokinetics. Seconday endpoints will evaluate muscle regeneration biomarkers, the change in UTRN...
...24-week data in 1Q18 and top-line 48-week data in 3Q18. Ezutromid is a small molecule utrophin (UTRN)...
...Product: Ezutromid (SMT C1100) (formerly BMN 195) Business: Musculoskeletal Molecular target: Utrophin (UTRN) Description: Small molecule UTRN...

...exclusive commercialization rights in Europe, Turkey and the Commonwealth of Independent States (CIS) to Summit’s utrophin (UTRN)...
...pipeline to treat Duchenne muscular dystrophy (DMD). The deal includes Summit’s ezutromid, a small molecule UTRN...
...million upon dosing of the last Phase II patient; and $290 million tied to additional utrophin...

...exclusive rights in Europe, Turkey and the Commonwealth of Independent States to Summit's utrophin ( UTRN...
...last PhaseOut DMD patient is dosed; and $290 million tied to Summit's next-generation small molecule utrophin...
...royalties up to a high teens percentage. Starting in 2018, Summit and Sarepta will split utrophin...